Across TCGA pan-cancer cohorts, MIR4484 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of MIR4484’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where MIR4484 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MIR4484 is over-expressed in tumor.
BRCA and LUSC are the cancer types where MIR4484 tumor–normal differential expression is most reproducible.